Last reviewed · How we verify

NCT04214873

Evaluation of the Effectiveness of the PiQo4 System for Reduction of Infra-orbital Pigmentation

Completed NA Last updated 3 October 2023
What this trial tests

NA trial testing PiQo4 Laser System in POH in 8 participants. Completed in 20 January 2022.

Timeline
6 January 2020
Primary endpoint
20 January 2022
20 January 2022

Quick facts

Lead sponsorFocus Medical, LLC
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment8
Start date6 January 2020
Primary completion20 January 2022
Estimated completion20 January 2022
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Focus Medical, LLC

Who can join

Adults 18 to 65, any sex, with POH. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A total of 10 healthy subjects at a single site, aged 18-65 years old and Fitzpatrick skin type I-IV with mild to moderate infra-orbital hyperpigmentation on the background of epidermal and/or dermal pigmentation that wish to improve their POH

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of PiQo4 Laser System

Trials testing the same drug.

Other Focus Medical, LLC trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04214873.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing